Non-executive Director Research Results 2021


This Research, conducted at our NED Forum, provides a fascinating insight into the challenges Boards and Non-executives continue to face as a result of the pandemic and the opportunities that lie ahead over the next 12 months.

Key findings from Criticaleye's NED Research:

  • For the first time, ESG is the top priority for Boards 
  • A third of Boards are considering replacing the CEO in the next 12-18 months
  • 74% of NEDs say that the quality of the ExCo debate on strategy needs to improve
  • 65% of NEDs expect investment in property and facilities to be cancelled or suspended 
  • 82% of NEDs are fully confident the Chair, CEO and CFO are aligned on strategy
  • 88% of Boards say more should be spent on leadership development for executives

Click here for the Criticaleye podcast. In episode one of our Leadership with New Horizons series, Criticaleye CEO Matthew Blagg and Director of Content Marc Barber cover key themes for leaders and senior executives in 2021.


Share this with your Community




Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

BLOG | What Sets World-Class CEOs Apart in Uncertain Times?

If you're a CEO today, you’re likely feeling the pressure to be a technologist, a geopolitical expert and a visionary all at once. Markets are shifting rapidly, the operating...


Click here to download this insight

Health and Wellbeing at Work

The CIPD’s 2025 Health and Wellbeing at Work report, supported by Criticaleye CPO Retreat 2026 Partner Simplyhealth, examines health, wellbeing and attendance trends and challenges. Now in its 24th edition, t...


Inspiring Leaders Podcast: Sally Bridgeland, Chair, Development Bank of Wales and Keith Cochrane, Chair, Schenck Process Group, on Risk in the Boardroom

In this episode, Sally Bridgeland, Chair, Development Bank of Wales, Nest Invest and BelleVie Care and Keith Cochrane, Chair, Schenck Process Group talk about what risks will be on the Board agenda this yea...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 231




Legal & General Drax Group plc Lightsource bp Worldpay NATS Canaccord Genuity Group Inc LACE Partners E.ON UK Aldermore Group London Stock Exchange Group Hitachi Solutions Rolls-Royce Mayborn Group NatWest Group GlaxoSmithKline plc British Land AlixPartners